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We examined gene expression in tree shrew choroid in response to three different myopiagenic condi-
tions: minus lens (ML) wear, form deprivation (FD), and continuous darkness (DK). Four groups of tree
shrews (n = 7 per group) were used. Starting 24 days after normal eye opening (days of visual experience
[DVE]), the ML group wore a monocular 5 D lens for 2 days. The FD group wore a monocular translucent
diffuser for 2 days. The DK group experienced continuous darkness binocularly for 11 days, starting at 17
DVE. An age-matched normal group was examined at 26 DVE. Quantitative PCR was used to measure the
relative (treated eye vs. control eye) differences in mRNA levels in the choroid for 77 candidate genes.
Small myopic changes were observed in the treated eyes (relative to the control eyes) of the ML group
(1.0 ± 0.2 D; mean ± SEM) and FD group (1.9 ± 0.2 D). A larger myopia developed in the DK group
(4.4 ± 1.0 D) relative to Normal eyes (both groups, mean of right and left eyes). In theML group, 28 genes
showed signiﬁcant differential mRNA expression; eighteen were down-regulated. A very similar pattern
occurred in the FD group; twenty-seven of the same genes were similarly regulated, along with ﬁve addi-
tional genes. Fewer expression differences in the DK group were signiﬁcant compared to normal or the
control eyes of the ML and FD groups, but the pattern was similar to that of the ML and FD differential
expression patterns. These data suggest that, at the level of the choroid, the gene expression signatures
produced by ‘‘GO’’ emmetropization signals are highly similar despite the different visual conditions.
 2014 Elsevier Ltd. All rights reserved.1. Introduction
It is well established that a visually-guided emmetropization
mechanism operates during post-natal visual development in a
wide range of vertebrate species, including humans (Mutti et al.,
2005; Norton, 1999; Schaeffel & Howland, 1988; Smith, Hung, &
Harwerth, 1999; Wallman & Winawer, 2004). This mechanism
uses refractive error, detected by the retina, to adjust the axial
elongation rate of the growing eye to achieve a match between
the location of the retina and that of the focal plane, reducing
the refractive error. Studies that either cut the optic nerve
(Raviola & Wiesel, 1985; Troilo, Gottlieb, & Wallman, 1987) or sup-
pressed retinal output (Norton, Essinger, & McBrien, 1994) have
found that there is a direct pathway within the eye: emmetropiza-
tion signals originate in the retina, pass into the retinal pigment
epithelium (RPE) and then into the choroid, ﬁnally reaching the
sclera. In tree shrews (mammals closely related to primates), stim-ulation of this pathway produces remodeling of the scleral extra-
cellular matrix that alters its biomechanical properties,
increasing the viscoelasticity and the axial elongation rate. We will
refer to this as the ‘‘direct emmetropization pathway’’ because it
can operate, albeit less well, in the absence of an ‘‘indirect’’ path-
way comprised of connections from the retina, through central
visual structures, that controls accommodation and other potential
outputs to the eye and can affect refractive development
(Dillingham, Guggenheim, & Erichsen, 2013; McFadden &
Wildsoet, 2009; Schaeffel et al., 1990; Wildsoet, 2003).
Minus lens (ML) wear and form deprivation (FD) are two treat-
ments often used to stimulate the emmetropization mechanism
(Wallman & Winawer, 2004). Wearing a minus lens, held in place
in front of the eye in a goggle frame, shifts the focal plane away
from the cornea, creating an artiﬁcially hyperopic refractive state.
This produces what has been described as a ‘‘GO’’ condition
(Rohrer et al., 1993; Schaeffel & Howland, 1988). In response, the
lens-wearing eye increases its axial elongation rate, moving the
retina to the shifted focal plane at which point the hyperopia is
eliminated and the GO condition has dissipated. When the minus
lens is removed, the treated eye is myopic. Form deprivation with
a translucent diffuser provides ample retinal illuminance but
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the retina. This also is a GO condition that causes an increase in
the axial elongation rate and myopia in the treated eye. However,
because elongation cannot restore clear retinal images, the GO con-
dition continues and the elongation rate remains elevated through-
out the treatment period.
A thirdprocedure, treatmentwithaperiodof continuousdarkness
(DK), also produces increased axial elongation in tree shrews and in
chicks. Tree shrews that were ﬁrst raised in standard colony lighting
with light-on and light-off periods, and then transferred to a com-
pletely dark environment, develop an increased axial elongation rate
and become myopic compared with age-matched normally-raised
animals (Norton, Amedo, & Siegwart, 2006). Chicks placed in DK also
exhibit increased axial elongation (Troilo & Wallman, 1991). How-
ever, prolonged DK treatment also produces ﬂattening of the cornea
so that the birds eventually become refractively hyperopic despite
having elongated eyes (Lauber, 1991). The retinal mechanism by
which darkness produces a GO condition is still unclear.
Based on behavioral and electrophysiological studies, ML and
FD treatments produce different, distinct patterns of excitation
and inhibition in the retina that are communicated through the
geniculostriate visual pathway to produce differing visual
responses. Several studies have suggested that the retinal emme-
tropization-related signaling produced by these two GO conditions
can be distinguished (Bartmann et al., 1994; Bitzer, Feldkaemper, &
Schaeffel, 2000; Fujikado et al., 1997; Kee, Marzani, & Wallman,
2001; Schaeffel et al., 1994; Wildsoet, 2003; Yew & Wildsoet,
2003). However, in the sclera, it has been found that ML and FD
produce nearly identical gene expression signatures; DK treatment
also produces a similar gene expression signature (Guo et al.,
2013). It appears that the different retinal activity produced by
these three myopiagenic conditions may be converted into a com-
mon set of emmetropization signals as it passes through the direct
RPE-choroid-sclera emmetropization pathway. Has this consolida-
tion into a common signal occurred at the level of the choroid, or
does the choroidal ‘‘compartment’’ of the emmetropization path-
way still distinguish amongst the visual conditions that produce
a retinally-generated GO condition?
Although changes in levels of proteins or other molecules pre-
sumably are key to actually transmitting signals from choroid to
sclera, it has been found that changes in mRNA levels can identify
the responses of the cells in tissues and are useful in identifying
pathways of interest (Gao et al., 2011, 2013; Schippert et al., 2006;
Shelton et al., 2008; Siegwart & Norton, 2005; Stone et al., 2011;
Zhang, Liu, &Wildsoet, 2012). In a previous paper in tree shrew cho-
roid (He et al., 2014), we examined the gene expression signatures
produced by ML wear (GO) and by recovery from induced myopia
(a STOP condition). Short-term ML treatment produced a GO gene
expression signature that was distinct from the STOP gene expres-
sion signature. These results, involving altered gene expression in
many genes, have shown that emmetropization-related signaling
can be detected in the choroidal compartment of the direct emme-
tropization pathway. The goal of the present study was to examine
alterations in gene expression in the choroid after 2 days ofMLwear,
2 days of FD, and after 11 days of DK treatment. The question asked
was whether the three GO conditions would produce the same, or
very similar, gene expression signatures?Fig. 1. Experimental groups and duration of treatments. The vertical bar indicates
the point when a dental acrylic pedestal was installed under anesthesia. Filled
regions indicate the type and duration of visual treatment. The right end of each bar
indicates the time point when mRNA levels were measured.2. Materials and methods
2.1. Experimental groups
The methods employed in this study were generally identical to
those in our previous paper (He et al., 2014). The juvenile tree
shrews (Tupaia glis belangeri) used in this study were produced inour breeding colony and raised by their mothers on a 14 h light/
10 h dark cycle. Tree shrew pups open their eyes about three weeks
after birth. The ﬁrst day both eyes are open is day one of visual
experience (DVE). All procedures complied with the ARVO State-
ment for the Use of Animals in Ophthalmic and Visual Research
and were approved by the Institutional Animal Care and Use Com-
mittee of the University of Alabama at Birmingham. Experimental
groups were balanced to include both males and females, and
avoided pups from the same parents wherever possible.
Therewere four groups of animals (n = 7per group) (Fig. 1). Start-
ing at 24 ± 1 DVE, the ML group wore a monocular 5 D (spherical
power) lens for 2 days; the FD group wore a monocular translucent
diffuser for 2 days; theDKgroupwas housed in continuousdarkness
for 11 days, starting at 17 ± 1 DVE. In the ML and FD groups, the
untreated fellow eye served as a control. A normal group (26N)
was also examined at 26 DVE. Data from the ML and 26N groups
were reported in the previous study (He et al., 2014) and are shown
here for direct comparison with the FD and DK group results.
2.2. Visual treatments
Animals in all groups were anesthetized (17.5 mg ketamine,
1.2 mg xylazine; supplemented with 0.5–2.0% isoﬂurane as
needed) and received a dental acrylic pedestal. For the ML and
FD groups, this occurred at 21 ± 1 DVE; in the DK group, the pedes-
tal was installed at 16 ± 1 DVE. After pedestal installation, all ani-
mals were placed in individual cages with standard colony
ﬂuorescent lighting (GE F34CW WM ECO cool white or F32T8/
25W/SPX41/ECO), 100–300 lux on the ﬂoor of the cage. In the ML
and FD groups, 3 days after pedestal installation, a goggle frame
holding a 5 D lens (12 mm diameter PMMA contact lens; Con-
forma Contact Lenses, Norfolk, VA) or a translucent diffuser was
clipped to the pedestal, ﬁrmly holding the lens or diffuser in front
of the randomly selected treated eye. The untreated fellow control
eye had unrestricted vision through the open goggle frame. Lenses
were cleaned twice daily (approximately 9:30 AM and 4:30 PM)
while diffusers were cleaned only in the morning. During cleaning,
goggles were brieﬂy (<3 min) removed under dim illumination and
animals were kept in a darkened nest box to minimize exposure to
visual stimuli. Animals in the DK group were transferred to contin-
uous darkness 1 day after pedestal installation (at 17 ± 1 DVE) and
checked daily with night-vision goggles and infrared illumination;
DK treatment ended after 11 days. The 26N group received a ped-
estal at 21 ± 1 DVE but did not wear a goggle.
2.3. Refractive and axial measures
Non-cycloplegic refractive measures were made, in awake ani-
mals, at the start and end of the treatment period with a Nidek
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FL). Normal animals were measured just before euthanasia. Cyclo-
plegic refractive measures were omitted to prevent any interfer-
ence by atropine on retino-scleral signaling (McKanna &
Casagrande, 1981). However, previous studies have shown that
non-cycloplegic measures provide a valid estimate of the refractive
state, and of induced myopia, in tree shrews (Norton, Siegwart, &
Amedo, 2006; Norton et al., 2000). All refractive values were cor-
rected to the corneal plane and for the small eye artifact
(Glickstein & Millodot, 1970), previously shown to be approxi-
mately +4 D in tree shrews (Norton, Wu, & Siegwart, 2003).
At the time the pedestal was attached, ocular component
dimensions were measured in most of the animals with a Lenstar
LS-900 optical biometer (Haag-Streit USA, Mason, OH) to ensure
that the two eyes did not differ signiﬁcantly in axial component
dimensions before treatment began. Post-treatment axial compo-
nent measures were also taken, except for one DK animal. The Len-
star optical biometer allowed these measures to be made quickly,
in awake animals, just before euthanasia.
2.4. Choroid dissection
On completion of the ﬁnal refractive measures, approximately
2–4 h into the light phase, animals were terminally anesthetized
(17.5 mg ketamine and 1.2 mg xylazine, followed by 50 mg xyla-
zine). DK animals were euthanized at similar times. Both eyes were
enucleated and placed into RNAlater solution (Life Technologies,
Carlsbad, CA). Extraocular muscles, conjunctiva, and orbital fat
were trimmed from the exterior surface of the eye and the cornea
dissected away just behind the corneoscleral junction. While view-
ing through a surgical microscope, the lens and vitreous humor
were removed; the retina and RPE, which were tightly bound to
each other, were then lifted from the eyecup. While still immersed
in RNAlater, choroid was teased from the scleral inner surface
using the rounded ends of forceps, collected, and then frozen in
liquid nitrogen. Because the dissection was extremely gentle, it is
possible that small portions of the lamina fusca, the outermost
layer of the choroid, may have adhered to the sclera in some cases
and, thus, not been included in our choroidal sample. Because the
retina/RPE separated cleanly from the choroid without dissection,
and because the inner surface of the sclera was not disrupted by
forceful scraping of the surface (and most scleral ﬁbroblasts are
within the layered matrix, not on the inner surface), there is no
reason to expect signiﬁcant contamination of the choroidal sam-
ples from either retina/RPE or sclera. As a further precaution,
RPE65 mRNA expression was measured in a group of 1-day ML ani-
mals for both the choroid and RPE, collected, as above, from the
same eye. Whilst RPE65 mRNA abundance was approximately
100 fold greater in RPE than in choroid, its differential (treated
vs. control eye) expression was not signiﬁcantly altered in RPE
but was signiﬁcantly up-regulated in the treated eyes of the cho-
roid sample (He et al., 2014). Thus, the RPE cannot be the source
of the mRNA for RPE65 in the choroid. We think it is therefore rea-
sonable to conclude that there was no signiﬁcant contamination of
our choroid sample with RPE.
2.5. Gene expression analysis
Each frozen choroid was homogenized with a disposable pestle
(Fisher Scientiﬁc, Pittsburgh, PA) from which total RNA was iso-
lated using a RiboPure kit (Life Technologies) according to the
manufacturer’s instructions, with the addition of an on-ﬁlter
DNase treatment. The puriﬁed RNA was quantiﬁed (NanoDrop
Technologies, Wilmington, DE), with an average yield per choroid
of 4.5 ± 1.2 lg (mean ± SD). RNA quality was conﬁrmed by dena-
turing gel electrophoresis (RNA FlashGel; Lonza, Rockland, ME).cDNA was synthesized from 1 lg of total RNA in a ﬁnal reaction
volume of 20 ll using a Superscript III RT kit (Life Technologies)
with minor modiﬁcations (2.5 lM anchored oligo (dT) 20 primers
and DTT omitted). The resultant cDNA was diluted 5-fold and
stored at 20 C until use.
Tree shrew-speciﬁc quantitative PCR (qPCR) primers were
designed for 77 genes of interest (Table 1) and the reference gene
RNA polymerase II (POLR2A) using Beacon Designer v7.7 (Premier
Biosoft International, Palo Alto, CA). None of the treatment condi-
tions affected the expression of the reference gene. Primer
sequences, amplicon size, and efﬁciencies are listed in Supplemen-
tary Table S1. The selected candidate genes included representa-
tives of three major groupings: signaling, metallopeptidases &
TIMPs, and extracellular matrix (ECM) proteins. They were selected
from genes that were found to change in preliminary studies of
tree shrew choroid during ML along with additional genes that
were suggested by a whole-transcriptome analysis of three of the
ML animals. All primers were designed to work under the same
cycling conditions. All amplicons were located within the coding
region and most spanned at least one intron; amplicon identity
was veriﬁed by gel electrophoresis and sequencing.
Relative gene expression was measured by qPCR on a StepOne-
Plus Real-Time PCR System using Power SYBR Green PCR Master
Mix (both, Life Technologies). Reactions were performed in tripli-
cate in a 15 ll volume containing 300 nM each primer and 0.4 ll
cDNA template. Cycling parameters were the same for all assays:
initial denaturation at 95 C for 10 min, followed by 40 cycles of
95 C for 15 s, 62 C for 60 s. Single gene products were obtained
for all reactions as assessed by melt curve analysis. Relative gene
expression was calculated using the DDCt method (Livak &
Schmittgen, 2001) to ﬁrst normalize the expression level of the tar-
get gene to that of the reference gene, and then to compare the rel-
ative expression of the target gene for treated vs. control eyes,
treated vs. normal eyes, and control vs. normal eyes. For DK ani-
mals the average of the right and left eyes was compared with nor-
mal eyes, and with the control eyes of the ML and FD groups. The
geometric group mean (for the 7 biological replicates) of these
expression ratios was used to calculate the fold change in gene
expression for each of the target genes.2.6. Statistical analysis
One-way analysis of variance (ANOVA; Statistica, Statsoft, Tulsa,
OK) was used to compare control and normal eye refractive data
across groups of animals; paired t-tests were used to determine
if signiﬁcant myopia (treated eye vs. control eye, DK vs. normal)
had developed. For gene expression data, paired t-tests were used
to assess treated eye vs. control eye differences; unpaired t-tests
were used to test for gene expression differences between all inde-
pendent groups. For both t-tests and ANOVA, p < 0.05 was consid-
ered signiﬁcant and no adjustment for possible false discovery rate
was applied. Linear regressions between expression differences
were made in SigmaPlot (Systat Software, San Jose, CA).3. Results
3.1. Refraction
The ﬁnal refractive values of the normal, treated, and control
eyes in the four groups are shown in Fig. 2. As expected in tree
shrews at 26 DVE, both eyes of the normal group were slightly
hyperopic (right eyes, 0.8 ± 0.4 D; left eyes, 1.3 ± 0.4 D; mean ± -
SEM). After 2 days of treatment, the ML treated eyes showed a
small, statistically-signiﬁcant myopic shift; the treated eyes were
1.0 ± 0.2 D myopic in comparison to the control eyes. After 2 days
Table 1
Genes examined by functional category, with cellular location of the protein encoded by the gene, and its UniProt accession ID.
Gene symbol Protein name Location UniProt ID
Signaling  cell surface
ADORA2A Adenosine receptor A2a Cell surface P29274
AQP4 Aquaporin 4 Cell surface P55087
CHRNA7 Cholinergic receptor, nicotinic a7 Cell surface P36544
DRD2 Dopamine receptor D2 Cell surface P14416
EPHA1 EPH receptor A1 Cell surface P21709
FGFR1 FGF receptor 1 Cell surface P11362
GFRA1 GDNF family receptor a1 Cell surface P56159
GRM5 Metabotropic glutamate receptor 5 Cell surface P41594
IGF2R Insulin-like growth factor 2 receptor Cell surface P11717
INSR Insulin receptor Cell surface P06213
OPN1LW Opsin 1, long-wave-sensitive Cell surface P04000
P2RY1 Purinergic receptor P2Y, G-protein coupled, 1 Cell surface P47900
SCUBE3 Signal peptide, CUB and EGF-like domain-containing protein 3 Cell surface Q8IX30
TNMD Tenomodulin Cell surface Q9H2S6
VIPR1 VIP receptor 1 Cell surface P32241
VIPR2 VIP receptor 2 Cell surface P41587
Signaling  intracellular
BCO2 Beta-carotene oxygenase 2 Intracellular Q9BYV7
CABP5 Calcium binding protein 5 Intracellular Q9NP86
CAMP Cathelicidin antimicrobial peptide Intracellular P49913
CDC42 Cell division cycle 42 Intracellular P60953
CHAT Choline O-acetyltransferase Intracellular P28329
CYP26B1 Cytochrome P450 26B1 Intracellular Q9NR63
NOS1 Nitric oxide synthase 1 Intracellular P29475
RASGRF1 Ras-speciﬁc guanine nucleotide-releasing factor 1 Intracellular Q13972
RLBP1 Retinaldehyde binding protein 1 Intracellular P12271
RPE65 Retinoid isomerohydrolase Intracellular Q16518
S100A12 Protein S100-A12 Intracellular P80511
ZNF185 Zinc ﬁnger protein 185 Intracellular O15231
Signaling  transcription regulators
EGR1 Early growth response protein 1 Intracellular P18146
HIF1A Hypoxia-inducible factor 1a Intracellular Q16665
PER2 Period circadian clock 2 Intracellular O15055
RXRB Retinoid X receptor b Intracellular P28702
VDR Vitamin D receptor Intracellular P11473
Signaling  secreted
ANGPTL7 Angiopoietin-related protein 7 Extracellular O43827
APOE Apolipoprotein E Extracellular P02649
BMP2 Bone morphogenetic protein 2 Extracellular P12643
BMP4 Bone morphogenetic protein 4 Extracellular P12644
CILP Cartilage intermediate layer protein 1 Extracellular O75339
EGF Epidermal growth factor Extracellular P01133
FAM180A Family with sequence similarity 180, member A Extracellular Q6UWF9
IGF2 Insulin-like growth factor 2 Extracellular P01344
IL1B Interleukin 1b Extracellular P01584
LTBP1 Latent TGFb binding protein 1 Extracellular Q14766
LTF Lactotransferrin Extracellular P02788
MEST Mesoderm speciﬁc transcript Extracellular Q5EB52
NRG1 Neuregulin 1 Extracellular Q02297
NTS Neurotensin Extracellular P30990
PENK Proenkephalin A Extracellular P01210
PI15 Peptidase inhibitor 15 Extracellular O43692
PTX3 Pentraxin 3 Extracellular P26022
SOSTDC1 Sclerostin domain-containing protein 1 Extracellular Q6X4U4
SST Somatostatin Extracellular P61278
TAC1 Protachykinin 1 Extracellular P20366
TGFB2 Transforming growth factor b2 Extracellular P61812
TGFB3 Transforming growth factor b3 Extracellular P10600
TGFBI TGFb-induced protein Extracellular Q15582
VIP Vasoactive intestinal peptide Extracellular P01282
Signaling  matricellular
CYR61 Protein CYR61 Extracellular O00622
NOV Nephroblastoma overexpressed gene Extracellular P48745
THBS1 Thrombospondin 1 Extracellular P07996
THBS2 Thrombospondin 2 Extracellular P35442
TNC Tenascin C Extracellular P24821
MP/TIMP
ADAMTS4 ADAM metallopeptidase with thrombospondin motif, 4 Extracellular O75173
ADAMTS5 ADAM metallopeptidase with thrombospondin motif, 5 Extracellular Q9UNA0
ADAMTSL3 ADAMTS-like 3 Extracellular P82987
MMP14 Matrix metallopeptidase 14 Cell surface P50281
(continued on next page)
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Table 1 (continued)
Gene symbol Protein name Location UniProt ID
TIMP2 TIMP metallopeptidase inhibitor 2 Extracellular P16035
TIMP3 TIMP metallopeptidase inhibitor 3 Extracellular P35625
Extracellular matrix
COL12A1 Collagen type XII, a1 Extracellular Q99715
COL6A6 Collagen type VI, a6 Extracellular A6NMZ7
DCN Decorin Extracellular P07585
FMOD Fibromodulin Extracellular Q06828
MXRA5 Matrix remodeling associated protein 5 Extracellular Q9NR99
NYX Nyctalopin Extracellular Q9GZU5
OGN Mimecan Extracellular P20774
PRELP Prolargin Extracellular P51888
SERPINH1 Serpin H1 Intracellular P50454
Fig. 2. End-of-treatment refractive measures for the normal, ML, FD, and DK
groups. Values are the mean refraction ± SEM for the right (R) and left (L) eyes of the
26N and DK groups or for the treated (T) and control (C) eyes of the ML and FD
groups. ML and FD treated eyes were signiﬁcantly different relative to control eyes;
the DK eyes were myopic compared with the eyes of the 26N group; indicated by
asterisks.
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niﬁcantly myopic (1.9 ± 0.2 D) relative to control eyes. After
11 days of dark treatment, the DK group exhibited a statistically-
signiﬁcant myopic shift (4.4 ± 1.0 D) compared with the 26N
group (both groups, mean of right and left eyes). The control eyes
in the ML and FD groups did not differ signiﬁcantly from the 26
DVE normal eyes (one-way ANOVA, p = 0.79).Fig. 3. Gene expression fold differences between right and left eyes for the (A) 26N grou
grouping of the protein products of the genes. Error bars = SEM. No gene showed signiﬁc
(2014).Ocular component dimensions, measured with the Lenstar, con-
ﬁrmed that the vitreous chamber of the treated eyes had elon-
gated, relative to the control eyes. In the ML group, the vitreous
chamber of the treated eyes (measured to the front of the retina)
was 0.016 ± 0.004 mm (mean ± SEM) larger than in the control
eyes. In the FD group, the treated eye vitreous chamber was
0.038 ± 0.011 mm longer than in the control eyes. The vitreous
chamber in the DK group (2.94 ± 0.03 mm) was signiﬁcantly larger
than the vitreous in the 26N group (2.86 ± 0.02 mm). It also was
signiﬁcantly longer than the vitreous chamber in the control eyes
of the ML (2.83 ± 0.02 mm) and FD (2.86 ± 0.02 mm) groups. Cor-
neal thickness, anterior chamber depth, and lens thickness did
not differ between treated vs. control eyes or between the 26N
and DK groups. The choroid was slightly thinner in the treated eyes
of the ML group (0.60 ± 0.005 lm vs. 0.65 ± 0.005 lm) and FD
group (0.58 ± 0.002 lm vs. 0.062 ± 0.003 lm) but the differences
were not statistically signiﬁcant. Thus, the refractive myopia was
primarily the result of a larger vitreous chamber depth.
3.2. Gene expression
3.2.1. Normal and DK groups
The mRNA levels in normal eyes, and the variability between
normal left and right eyes, can provide a basis for comparison with
the levels and variability found in treated and control eyes. Fig. 3A
compares gene expression in the left and right eyes of the 26N
group reported previously (He et al., 2014). Expression values forp and (B) DK group. Headings separated by vertical dashed lines indicate functional
ant regulation in either group. The data shown in (A) are reproduced from He et al.
Table 2
Gene expression differences comparing right vs. left, treated vs. control, treated vs. normal, and control vs. normal eyes. MLC = ML control eye, FDC = FD control eye. Red
text = signiﬁcant down-regulation, blue = signiﬁcant up-regulation, grey = expression difference not statistically signiﬁcant. ‘‘X’’ = differential expression likely due to
control eye effect.
26N DK
RE vs. LE T vs. C T vs. N C vs. N T vs. C T vs. N C vs. N T vs. MLC T vs. FDC T vs. 26N RE vs. LE
Signaling − Cell surface
ADORA2A  1.06 -1.24 -1.88 -1.52 -1.01  1.57  1.58  1.37 -1.74 -1.10 -1.32
AQP4  1.50  1.46  1.65  1.12  1.38 -1.24 -1.72 -1.74  1.11 -1.55  1.31
CHRNA7 -1.03  1.15  1.42  1.23  1.02  1.19  1.17  1.57  1.50  1.94  1.00
DRD2  1.21  1.68  1.70  1.01  1.07  1.00 -1.06 -1.18 -1.10 -1.17 -1.04
EPHA1  1.01 -1.55 -1.75 -1.13 -1.85 -1.81  1.02 -1.84 -2.13 -2.09 -1.05
FGFR1 -1.05 -1.68 -1.87 -1.11 -1.14 -1.43 -1.25 -1.47 -1.30 -1.63  1.05
GFRA1  1.22 -1.12 -1.18 -1.05  1.05 -1.00 -1.06 -1.44 -1.44 -1.52 -1.17
GRM5  1.57  1.34  1.50  1.12 -1.36  1.34  1.83 -1.26 -2.06 -1.13 -1.05
IGF2R  1.01 -1.16  1.01  1.17  1.03  1.34  1.31 -1.07 -1.19  1.10 -1.01
INSR  1.07 -1.49 -1.76 -1.18  1.10  1.21  1.10 -1.24 -1.45 -1.46 -1.05
OPN1LW  1.12  1.13  1.07 -1.06  1.80  1.00 -1.79 -1.59  1.06 -1.69  1.00
P2RY1  1.12  1.29 -1.24 -1.60  1.31  1.24 -1.06  1.24 -1.22 -1.29  1.06
SCUBE3 -1.00 -1.62 -1.28  1.27 -1.70 -1.13  1.50 -2.53 -3.00 -2.00 -1.13
TNMD  1.06 -1.27 -2.23 -1.76 -1.69 -2.59 -1.53 -1.06 -1.22 -1.86  1.22
VIPR1  1.24  1.11  1.03 -1.07  1.37 -1.60 -2.19 -1.03  1.98 -1.11 -1.08
VIPR2  1.22 -1.55 -1.63 -1.05 -1.23 -1.26 -1.02  1.06  1.03  1.01  1.02
Signaling − Intracellular
BCO2  1.06 -1.48 -1.33  1.11 -1.60 -1.10  1.46 -1.37 -1.79 -1.23  1.08
CABP5  1.74  2.14  2.14  1.00 -1.27 -1.38 -1.09 -1.15 -1.05 -1.15 -1.19
CAMP -1.19  2.25  4.00  1.78 -1.39  1.63  2.27  1.05 -1.22  1.86 -1.11
CDC42  1.02 -1.25 -1.46 -1.16 -1.05  1.02  1.07  1.18 -1.05  1.02 -1.07
CHAT  1.49  1.22  1.70  1.39 -1.36  1.36  1.84 -1.33 -1.76  1.05 -1.24
CYP26B1  1.31 -4.05 -3.28  1.24 -2.32 -2.16  1.07 -5.34 -4.64 -4.32 -1.22
NOS1 -1.27  1.53 -1.62 -2.46  1.25 -2.44 -3.07 -2.19 -1.76 -5.39  1.16
RASGRF1  1.26  1.06  1.43  1.34 -1.29  1.57  2.03  1.29 -1.17  1.73 -1.13
RLBP1  1.14     2.76 x -1.22 -3.37     4.10 x -2.80 -11.47 -1.51  2.26 -5.08  1.06
RPE65  1.20  2.28  1.59 -1.43     4.80 x  1.56 -3.08  1.40  3.02 -1.02 -1.31
S100A12 -1.04  1.62  2.34  1.45 -1.50  1.60  2.40 -1.39 -2.31  1.04 -1.05
ZNF185  1.01 -1.35 -1.62 -1.20 -1.36 -1.22  1.12 -1.75 -2.35 -2.10 -1.11
Signaling − Transcription
EGR1  1.05 -1.33 -1.42 -1.07 -1.31 -1.53 -1.17  1.23  1.33  1.14  1.04
HIF1A  1.07  1.20  1.07 -1.12  1.11  1.09 -1.02  1.22  1.12  1.09  1.03
PER2  1.02 -1.35 -1.36 -1.01 -1.06  1.27  1.35 -1.52 -2.09 -1.54 -1.00
RXRB  1.05 -1.22 -1.28 -1.05  1.01  1.13  1.11  1.17 -1.13 -1.01  1.07
VDR -1.12 -1.69 -1.86 -1.10 -1.03 -1.12 -1.09 -1.27 -1.28 -1.40 -1.03
Signaling − Secreted
ANGPTL7  1.11  1.27  1.17 -1.09  1.49  1.16 -1.29  1.44  1.70  1.32  1.06
APOE  1.04  1.49  2.83  1.90  1.20 -1.74 -2.09 -1.18  3.36  1.61  1.13
BMP2  1.09  1.54  1.18 -1.30     1.91 x  1.13 -1.70  1.40  1.83  1.08  1.00
BMP4 -1.08  1.48  1.48  1.00  1.58  2.02  1.28  3.41  2.68  3.42 -1.16
CILP  1.31 -3.00 -2.52  1.19 -3.03 -2.11  1.43 -2.39 -2.88 -2.01 -1.01
EGF  1.16  2.09  1.38 -1.51  4.13  1.49 -2.77 -8.47 -4.62 -12.79 -1.21
FAM180A  1.03 -1.60 -1.58  1.01 -1.49 -1.34  1.11 -1.78 -1.96 -1.76 -1.08
IGF2  1.01  1.24  1.44  1.16  1.32  1.41  1.07  1.14  1.23  1.32  1.02
IL1B  1.10  1.05  1.16  1.11  1.09  1.40  1.28  1.43  1.24  1.58 -1.03
LTBP1 -1.05  1.03 -1.15 -1.19  1.01 -1.08 -1.09 -1.02 -1.12 -1.22  1.02
LTF -1.19  1.36  2.20  1.62 -1.32  1.21  1.59 -1.74 -1.71 -1.08  1.01
MEST -1.02 -1.64 -1.55  1.06 -2.30 -1.94  1.19 -2.16 -2.41 -2.03 -1.01
NRG1  1.09  1.47  1.55  1.06  1.52  1.76  1.16  2.38  2.17  2.52 -1.02
NTS  1.15  1.41  1.03 -1.36  1.37 -1.01 -1.39  1.63  1.67 1.20 -1.12
PENK  1.06 -1.73 -1.90 -1.09 -1.60 -1.13  1.41 -1.96 -3.03 -2.14 -1.06
PI15  1.22  3.41  2.87 -1.19  5.84  6.56  1.12  3.19  2.39  2.68 -1.00
PTX3  1.10 -3.48 -2.25  1.55 -3.77 -2.45  1.54 -3.09 -3.08 -2.00  1.07
SOSTDC1  1.04 -1.70 -2.22 -1.31 -2.30 -1.74  1.32 -1.01 -1.74 -1.32 -1.01
SST -1.02 -1.45 -1.17  1.25 -2.12 -3.16 -1.49 -3.79 -2.04 -3.04 -1.15
TAC1  1.35  1.22  1.28  1.05 -1.03  1.02  1.06 -1.25 -1.26 -1.19  1.01
TGFB2 -1.12 -1.03 -1.72 -1.67  1.09 -1.56 -1.71  1.44  1.47 -1.16 -1.01
TGFB3 -1.10 -1.07  1.03  1.10  1.07 -1.46 -1.56 -1.36  1.26 -1.24 -1.07
TGFBI  1.06  1.46  1.48  1.02  1.61  1.44 -1.12  1.57  1.78  1.59  1.00
VIP  1.62  1.03 -1.10 -1.13 -1.57 -1.45  1.09  1.14 -1.08  1.00 -1.09
Signaling − Matricellular
CYR61  1.15 -1.63 -1.20  1.35 -2.15 -1.75  1.23 -1.41 -1.28 -1.04  1.10
NOV  1.11 -2.14 -2.75 -1.28 -1.99 -2.68 -1.34 -1.51 -1.44 -1.93 -1.11
THBS1  1.11 -2.97 -3.08 -1.04 -1.90 -1.96 -1.03 -1.30 -1.31 -1.35  1.04
THBS2  1.04 -1.98 -2.25 -1.14  1.02  1.13  1.10  1.16 -1.08  1.02  1.04
TNC -1.12 -1.24  1.21  1.49  1.20 -1.19 -1.43 -1.22  1.43  1.22 -1.15
MP / TIMP
ADAMTS4 -1.03 -1.33  1.08  1.44 -1.00 -1.05 -1.05 -1.08  1.39  1.33 -1.10
ADAMTS5 -1.03 -1.06 -1.20 -1.13  1.03 -1.25 -1.28  1.04  1.17 -1.09 -1.02
ADAMTSL3  1.02 -1.99 -1.20  1.65 -1.85 -1.19  1.55 -1.69 -1.59 -1.02 -1.01
MMP14  1.07  1.14  1.05 -1.09  1.27  1.08 -1.18 -1.05  1.04 -1.14  1.03
TIMP2 -1.01 -1.42 -1.29  1.09  1.12  1.08 -1.04  1.12  1.27  1.23  1.06
TIMP3 -1.05 -1.28 -1.53 -1.20 -1.07  1.05  1.12  1.03 -1.12 -1.01  1.03
Extracellular matrix
COL12A1  1.08 -1.90 -1.97 -1.04 -1.49 -1.40  1.07  1.05 -1.05  1.01  1.08
COL6A6  1.04 -1.83 -1.35  1.35 -1.76 -1.12  1.58 -1.63 -1.90 -1.21 -1.23
DCN  1.09  1.07  1.08  1.00  1.06  1.16  1.09  1.21  1.11  1.21  1.01
FMOD  1.01 -1.19 -1.82 -1.52 -1.15 -1.87 -1.63 -1.20 -1.12 -1.83  1.03
MXRA5 -1.03 -1.18 -1.04  1.13 -1.02  1.11  1.13 -1.26 -1.26 -1.12  1.00
NYX  1.09 -1.09 -1.26 -1.16 -1.06  1.35  1.43  1.18 -1.27  1.02 -1.02
OGN  1.00 -1.32 -1.70 -1.29 -1.37 -1.26  1.08 -1.08 -1.50 -1.38  1.03
PRELP -1.02 -1.08 -1.29 -1.20  1.10  1.23  1.12  1.13 -1.19 -1.06  1.06
SERPINH1  1.00 -1.12 -1.09  1.03 -1.08  1.39  1.50  1.16 -1.26  1.19  1.05
ML FD DK
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signiﬁcantly between left and right eyes for any of the 77 genes.
Fig. 3B compares gene expression in the left and right eyes of the
DK group. There were no signiﬁcant differences between left and
right eye mRNA levels for any of the 77 genes. Thus, the differences
found in the treatment groups can be attributed to the experimen-
tal conditions.3.2.2. ML and FD groups
The ML group (Fig. 4A) had a signiﬁcant difference in mRNA
expression levels between the treated and control eyes for 28
genes; 18 of these genes were down-regulated. Expression values
are listed in Table 2.
The FD group (Fig. 4B) had a pattern of differential mRNA
expression that was very similar to that in the ML group in terms
of which genes did, and did not, show signiﬁcant differential
expression, the direction of the differential expression, and, gener-
ally, in the magnitude of that fold difference. Twenty-seven genes
were differentially expressed in both; 17 were down-regulated. In
addition, mRNA levels for 5 genes were signiﬁcantly affected in
the FD group that were not altered in the ML group: VIPR2, EGR1,
and COL12A1 were down-regulated; EGF and MMP14 were signiﬁ-
cantly up-regulated. One gene (TIMP3) was signiﬁcantly down-reg-
ulated in ML animals but not altered in the FD group treated eyes.
In almost all cases in both the ML and FD groups, the control eye
gene expression was not signiﬁcantly different from that in the
26N group, suggesting that treated vs. control differences are due
to a change in the treated eye. For one gene (RLBP1) in the ML
group the differential effect occurred because control eye, but
not treated eye, mRNA levels were signiﬁcantly different from
the 26N group. In the FD group, this was the case for three genes
(RLBP1, RPE65, and BMP2), as indicated in Fig. 4 and Table 2.Fig. 4. Gene expression fold differences between the treated and control eyes for the (A
functional grouping of the protein products of the genes. Filled bars represent statisticall
arbitrary and intended to help in comparing the same gene in the two different conditions
eye difference was a result of the control eye differing from normal (Table 2). The data3.2.3. Comparison between ML and FD GO signatures
The similarities in the mRNA expression patterns in the ML and
FD groups are illustrated in Fig. 5, which compares differential
expression in the ML group (Fig. 4A) with the differential expres-
sion in the FD group (Fig. 4B) for the 33 genes whose expression
was signiﬁcantly altered in either group. All of the genes were reg-
ulated in the same direction in both conditions and generally by
very similar amounts. The correlation was signiﬁcant (p < 0.0001)
with r2 = 0.79. Although the direction of the shared differential
expression was the same for these genes, the amplitude (of the fold
differences) differed for several genes. PI15, RPE65, RLBP1, and EGF
were more strongly up-regulated in the FD group than in the ML
group. THBS1 and CYP26B1 were more strongly down-regulated
in the ML group than in the FD group.3.2.4. DK group
Because the DK group received binocular treatment, there was
not a within-animal control for comparison. In Fig. 6, the gene
expression in the DK group (mean of right and left eyes) was com-
pared with the three possible control groups: the control eyes of
the ML group (Fig. 6A), the control eyes of the FD group (Fig. 6B),
and with the 26N group (mean of right and left eyes) (Fig. 6C). Fold
differences for these comparisons are given in Table 2. It is evident
in Fig. 6 that similar patterns occurred regardless of which eyes
were used as a comparison. Fewer fold differences were statisti-
cally signiﬁcant than in the ML and FD groups treated vs. control
eye comparisons, presumably because comparisons were made
across groups of animals, rather than within animals. However, 4
genes were signiﬁcantly regulated in the DK group in all three of
the comparisons in Fig. 6: CYP26B1, EGF, and PTX3 were down-reg-
ulated, while BMP4 was up-regulated. Whilst EGF was strongly
down-regulated in the DK group in comparison with the ML con-) ML group and (B) FD group. Headings separated by vertical dashed lines indicate
y signiﬁcant differences between the treated and control eyes (p < 0.05). Bar color is
. Error bars = SEM. The X’s indicate genes for which the signiﬁcant treated vs. control
shown in (A) are reproduced from He et al. (2014).
Fig. 5. Comparison of the gene expression differences (treated eye vs. control eye)
in Fig. 4A (ML) with the differences in Fig. 4B (FD), showing the similar differential
expression patterns in the two GO conditions. Values near the dashed line indicate
genes that responded similarly in the two conditions. Stars = signiﬁcant differences
for both ML and FD; triangles = signiﬁcant differences only for ML; squares =
signiﬁcant differences only for FD.
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up-regulated in the treated vs. control eyes of the FD group.3.2.5. Comparison of DK GO signature with ML and FD GO signatures
Gene expression in the DK group eyes, compared with either
the ML or FD control eyes, was similar to that found for the treated
vs. control differences for the ML and FD groups. Fig. 7 is organized
similarly to Fig. 5. Fig. 7A plots the DK group (relative to the ML
control eyes) (Fig. 6A) against the ML treated vs. control eye fold
differences (Fig. 4A). Included in the ﬁgure are 31 genes that were
signiﬁcantly regulated in either ML (T vs. C), DK relative to the ML
control eyes, or both. Fig. 7B plots the DK group (relative to the FD
control eyes) (Fig. 6B) against the FD treated vs. control eye differ-
ences (Fig. 4B), including 34 genes which were signiﬁcantly regu-
lated in either FD (T vs. C), DK relative to the FD control eyes, or
both. Fig. 7A and B are similar. The comparisons of gene expression
in the DK group with the ML and FD groups are more variable than
was the comparison between the ML and FD groups (Fig. 5). Yet,
the fold differences for nearly all genes are in the upper right or
lower left quadrant indicating that they were up- or down-regu-
lated in both DK and ML groups (Fig. 7A) or in both the DK and
FD groups (Fig. 7B). The notable exception, in Fig. 7B, is EGF, which
was signiﬁcantly up-regulated in the FD group but down-regulated
in the DK group. Also in Fig 7A, EGF is strongly down-regulated in
the DK group (8.47) and so is not shown given the ﬁgure’s scale.
The correlations (excluding EGF) were signiﬁcant in both Fig. 7A
(p < 0.0001, r2 = 0.50) and Fig. 7B (p < 0.0001, r2 = 0.51).4. Discussion
4.1. A common choroidal GO signature?
In response to myopiagenic visual stimuli, the retinal compart-
ment of the direct emmetropization pathway generates GO signals
that are conveyed into the RPE (He, Frost, & Norton, 2014), thence
into the choroid (He et al., 2014), and eventually reach the sclera
(Guo et al., 2013) where they modulate the axial elongation rate
of the growing postnatal eye (Siegwart & Norton, 1998). It seemsevident that the three GO conditions used in this study, minus lens
wear, form deprivation, and continuous darkness, must produce
dramatically different responses in many of the retinal horizontal,
bipolar, and amacrine cells and in the patterns of retinal ganglion
cell activity that are sent through the optic nerve to central visual
structures, yet all three produce a nearly identical response in the
scleral ﬁbroblasts (Guo et al., 2013). There is evidence in chicks
that the emmetropization-related signaling may differ between
ML and FD conditions, but this is a topic of ongoing debate
(Morgan, Ashby, & Nickla, 2013). If they do differ, it seems likely
that the differences are in the responses of retinal neurons, whose
inﬂuence is then passed on to the RPE and choroid.
To what degree does the direct emmetropization pathway (as
described in the Introduction) distinguish between these different
myopiagenic visual conditions after the signals leave the retina?
Although efferent inﬂuences to the choroid from the ‘‘indirect’’
emmetropization pathway cannot be completely ruled out, the
present results suggest that the direct emmetropization mecha-
nism may not distinguish between the different visual stimuli.
Similarly, at the level of the scleral ﬁbroblast response Guo et al.
(2013) found in tree shrews that ML and FD produce virtually iden-
tical scleral gene expression signatures in a sample of 55 genes,
and that DK also produces a very similar gene expression pattern.
It thus seems relevant to assess whether these three GO conditions
produce distinct or similar gene expression patterns in the choroid,
which presumably is the primary source of the signals that pro-
duce the scleral ﬁbroblast response.
The present study found that the three GO conditions produce
very similar gene expression signatures in our sample of 77 genes
in the choroid. The ML and FD gene expression signatures are
extremely similar. These similarities extend not only to which
genes are differentially expressed, and the magnitude of the fold
differences, but also to which genes in the sample did not show
signiﬁcant differential expression. The DK signature may be less
similar, but it is difﬁcult to be certain without having a within-ani-
mal control eye for comparison.
We found only limited evidence of genes that respond speciﬁ-
cally to one GO condition but not the others. mRNA expression
for EGF was signiﬁcantly up-regulated (4.13-fold) in FD. It was also
up-regulated (2.09-fold) in ML, but the up-regulation was not sta-
tistically signiﬁcant. Whether this represents a real difference
between these conditions, or was due to variability in the relatively
small groups of seven animals is unclear. However, EGF was dra-
matically down-regulated in DK choroid when compared with
the ML control eyes (8.47-fold), FD control eyes (4.62-fold),
and normal eyes (12.79-fold). Evidence for other possible differ-
ences is less compelling; mRNA levels for three additional genes,
NOS1, PER2, and SST, were signiﬁcantly down-regulated in the
DK eyes in two of the three comparisons but not altered in ML or
FD. mRNA for APOE was signiﬁcantly up-regulated in one of the
three comparisons (DK vs. the FD control eyes); it was not regu-
lated in the treated eyes vs. control eyes of the ML and FD groups.
Thus, mRNA for EGF, in the DK group, was the only example in the
present study of a gene whose regulation might be related to a par-
ticular myopiagenic visual condition. However, the overall similar-
ity of the three choroidal GO gene expression signatures suggests
that the details of the visual conditions that produce the initial
GO signal in the retina are substantially less important in the cho-
roid than they are in the retina.
4.2. Components of the GO signal
A reason to examine the response in choroid to these three
myopiagenic stimuli is to learn if there is an essential ‘‘core’’ of
key genes that modulate the signaling cascade into the sclera,
causing it to remodel, and increasing the rate of axial elongation.
Fig. 6. Gene expression fold differences. (A) DK group (mean of the R and L eyes) vs. ML control eyes. (B) DK group vs. FD control eyes. (C) DK group vs. the 26N group (mean
of the R and L eyes). Headings separated by vertical dashed lines indicate functional grouping of the protein products of the genes. Filled bars represent statistically signiﬁcant
differences (p < 0.05). Bar color is arbitrary and intended to help in comparing the same gene in the three different conditions. Error bars = SEM. In (A and C), the off-scale fold
differences for EGF are indicated next to the bar.
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to be the changes that occur in all three myopiagenic conditions.
Table 3 shows those genes from our sample whose mRNA levels
were signiﬁcantly modulated during GO. Three genes were consis-
tently modulated in the same direction in all three GO conditions
(shaded in Table 3): the treated vs. control eyes of the ML and FD
groups, and in the DK treated eyes when compared with all three
possible ‘‘control’’ eyes. mRNA for CYP26B1 and PTX3 were
down-regulated and mRNA for BMP4 was up-regulated. Using a
less stringent criterion, signiﬁcant differences in mRNA levels in
the ML, FD, and two of the three DK group comparisons, six addi-
tional genes could be included in the core of the potential GO sig-
nal/response. EPHA1, SCUBE3, ZNF185, and MEST were down-
regulated; NRG1 and PI15 were up-regulated.
The suggestion that these genes might be the essential compo-
nents of a choroidal GO response must be tempered by several lim-
itations. One is that the ‘‘essential GO’’ signal may change over
time and may also reﬂect the ‘‘strength’’ of the GO signal. The ML
and FD groups were examined after 2 days of treatment, and devel-oped slightly different amounts of myopia (1.0 ± 0.2 D vs.
1.9 ± 0.2 D). The similarity of the mRNA signatures (Fig. 5) may
reﬂect that very similar alterations in gene expression are impor-
tant early in the development of induced myopia. The differences
in expression levels of a few more strongly-affected genes (Fig. 5)
may reﬂect their importance in the amount or rate of myopia
development. For instance, the stronger up-regulation of PI15,
RPE65, RLBP1, and EGF in the FD group may suggest that they
are involved in the higher rate of axial elongation and myopia
development. The lower down-regulation of THBS1 and CYP26B1
during FD may also contribute to the more rapid myopia develop-
ment. The DK group experienced a longer (11 day) treatment per-
iod. As is the case with form deprivation, whatever signal is
produced by continuous darkness to cause increased axial elonga-
tion did not change over time – the darkness was continuous
throughout the treatment period. Thus is seems that the choroids
in the DK group likely were in the same ‘‘GO’’ situation after
11 days as they were earlier in the treatment period. However, if
the choroidal response to the GO condition changes with the dura-
Fig. 7. Comparison of the gene expression differences for (A) Fig. 4A (ML treated eyes vs. control eyes) with the differences in Fig. 6A (DK vs. ML control eyes; MLC) and (B)
Fig. 4B (FD treated eyes vs. control eyes) with the differences in Fig. 6B (DK vs. FD control eyes; FDC). Values near the dashed line indicate genes that responded with similar
fold differences in the two conditions. Stars = signiﬁcant fold differences for both ML and DK (in A) or both FD and DK (in B); triangles = signiﬁcant fold differences only for ML
or FD; squares = signiﬁcant fold differences only for DK.
Table 3
Genes that were signiﬁcantly regulated under ML and FD (treated vs. control) or DK (vs. ML control, FD control, or Normal)
conditions. Bold red gene symbols = down-regulation, italicised blue = up-regulation, grey shading = signiﬁcant regulation in all
ﬁve comparisons.
ML FD
vs. MLC vs. FDC vs. 26N
EPHA1 EPHA1 EPHA1 EPHA1
SCUBE3 SCUBE3 SCUBE3 SCUBE3
VIPR2
P2RY1 P2RY1
BCO2 BCO2
CYP26B1 CYP26B1 CYP26B1 CYP26B1 CYP26B1
ZNF185 ZNF185 ZNF185 ZNF185
NOS1 NOS1
RLBP1 RLBP1 RLBP1
RPE65 RPE65 RPE65
EGR1
PER2 PER2
HIF1A HIF1A
CILP CILP
FAM180A FAM180A
MEST MEST MEST MEST
PENK PENK PENK
PTX3 PTX3 PTX3 PTX3 PTX3
SOSTDC1 SOSTDC1
SST SST
APOE
BMP2 BMP2 BMP2
BMP4 BMP4 BMP4 BMP4 BMP4
IGF2 IGF2
NRG1 NRG1 NRG1 NRG1
PI15 PI15 PI15 PI15
TGFBI TGFBI
EGF EGF EGF EGF
CYR61 CYR61
NOV NOV
THBS1 THBS1
ADAMTSL3 ADAMTSL3
TIMP3
MMP14
COL6A6 COL6A6
OGN OGN OGN
COL12A1
FMOD
 Signaling - Secreted
 Signaling - Matricellular
 MP / TIMP
 Extracellular matrix
 Functional category
DK
 Signaling - Cell surface
 Signaling - Intracellular
 Signaling - Transcription
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62 L. He et al. / Vision Research 102 (2014) 52–63tion of treatment, it might help account for the less similar constel-
lation of differentially expressed genes compared with the FD and
ML groups. For instance, the dramatic down-regulation of EGF after
11 days of DKmay be a late-developing signal related to alterations
in circadian signaling (Morgan, Ashby, & Nickla, 2013; Nickla,
Wildsoet, & Wallman, 1998).
It also is possible that some of the shared gene expression
changes occur because the choroid physically responds similarly
in all three myopiagenic conditions (Nickla & Wallman, 2010;
Summers, 2013) in ways that may, or may not, be part of the
emmetropization signaling cascade. Although the choroid is much
thinner in mammals than in chicks, there is evidence in tree
shrews (Siegwart & Norton, 1998) that, as in chick, it becomes thin-
ner during myopia development (though the thinning was not sta-
tistically signiﬁcant in the present study). In chicks, there is
reduced choroidal blood ﬂow and there could be remodeling of
the choroidal extracellular matrix (Summers, 2013). A subset of
ten genes in our sample that were signiﬁcantly altered in GO con-
ditions play a role in vascular regulation and/or angiogenesis
(BMP2, BMP4, CYR61, EGF, HIF1A, IGF2, NRG1, PTX3, THBS1, and
TIMP3); the altered mRNA level for these genes may have been
part of a common choroidal response. It is, of course, unknown if
such vascular and/or extracellular matrix changes may not only
be part of a local choroidal response, but also part of the emme-
tropization signal as well. To directly test the possibility that the
shared gene expression changes may reﬂect simply changes in cho-
roidal thinning or vascular ﬂow, future studies might examine
these genes in treatments in which the eye elongates without cho-
roidal thinning, or slows its elongation without choroidal thicken-
ing (Nickla & Wallman, 2010). It also could not be distinguished in
this study the degree to which the choroidal signatures represent
the response of choroidal cells to incoming signals from the RPE
and the degree to which they are involved in generating signals
that are transmitted to the sclera.
An additional limitation in the ability to deﬁne the key genes
involved in the choroidal compartment of the direct emmetropiza-
tion pathway is that although our sample is large enough to show
that there are similarities and, potentially, to have found differ-
ences if they exist, this is nonetheless a relatively small sample.
A preliminary whole-transcriptome analysis using mRNA from
three of the ML animals suggested that over 300 distinct genes
(from the just over 14,000 found to be expressed in the tree shrew
choroid) may be up- or down-regulated by at least 1.2-fold (Frost,
personal communication, 2013). It may be that genes not included
in our sample also respond in the same way to ML, FD, and DK and
thus are part of a ‘‘core’’ of genes in the choroidal compartment of
the direct emmetropization pathway.
If, as the data of this study suggest, there is a consistent group of
geneswhose expression responds in the samemanner toML, FD, and
DK, itwould raise thequestion ofwhether the incoming signals from
RPE do, or do not, distinguish between these conditions?Once infor-
mation about defocus has been extracted by retinal neurons, how
important, for the direct emmetropization pathway, are the details
of the visual scene? The emmetropization mechanism seems to
function in awide range of vertebrate species that exist inmany dif-
ferent visual environments. The visual system uses channels com-
prised of differing neurons to respond to light increments and
decrements, to color, direction of motion, etc. Neurons in these
channels are specialized to respond to stimuli matched to their
receptive-ﬁeld properties; they have limited sensitivity to other
characteristics of the visual scene. Similarly, perhaps, the direct
emmetropization pathwaymay retain only the defocus-related sig-
naling and be insensitive to the visual details. Thus far, we only have
evidence in tree shrew choroid and sclera suggesting that vision-
speciﬁc information may not be encoded. It will be interesting to
learn if this is also the case in other species and also in the RPE.Acknowledgments
This study was supported by NIH Grants EY005922 and
EY003039 (P30). Li He was supported in part by a supplement to
EY005922 and by funds from the Department of Vision Sciences.
This work was performed in partial fulﬁllment of the requirements
for the degree of Doctor of Philosophy at the University of Alabama
at Birmingham (Li He). Preliminary results were presented in
abstract form (the 14th International Myopia Conference, 2013).Appendix A. Supplementary material
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.visres.2014.
07.005.
References
Bartmann, M., Schaeffel, F., Hagel, G., & Zrenner, E. (1994). Constant light affects
retinal dopamine levels and blocks deprivation myopia but not lens-induced
refractive errors in chickens. Visual Neuroscience, 11, 199–208.
Bitzer, M., Feldkaemper, M., & Schaeffel, F. (2000). Visually induced changes in
components of the retinoic acid system in fundal layers of the chick.
Experimental Eye Research, 70, 97–106.
Dillingham, C. M., Guggenheim, J. A., & Erichsen, J. T. (2013). Disruption of the
centrifugal visual system inhibits early eye growth in chicks. Investigative
Ophthalmology & Visual Science, 54, 3632–3643.
Fujikado, T., Kawasaki, Y., Suzuki, A., Ohmi, G., & Tano, Y. (1997). Retinal function
with lens-induced myopia compared with form-deprivation myopia in chicks.
Graefes Archive for Clinical and Experimental Ophthalmology, 235, 320–324.
Gao, H., Frost, M. R., Siegwart, J. T., Jr., & Norton, T. T. (2011). Patterns of mRNA and
protein expression during minus-lens compensation and recovery in tree shrew
sclera. Molecular Vision, 17, 903–919.
Glickstein, M., & Millodot, M. (1970). Retinoscopy and eye size. Science, 168,
605–606.
Guo, L., Frost, M. R., He, L., Siegwart, J. T., Jr., & Norton, T. T. (2013). Gene expression
signatures in tree shrew sclera in response to three myopiagenic conditions.
Investigative Ophthalmology & Visual Science, 54, 6806–6819.
He, L., Frost, M. R., & Norton, T. T. (2014). Differential gene expression in tree shrew
retina compared with retinal pigment epithelium (RPE) in response to six hours
of minus-lens wear. Investigative Ophthalmology & Visual Science, 55. ARVO E-
Abstract 3037.
He, L., Frost, M. R., Siegwart, J. T., Jr., & Norton, T. T. (2014). Gene expression
signatures in tree shrew choroid during lens-induced myopia and recovery.
Experimental Eye Research, 123, 56–71.
Kee, C. S., Marzani, D., & Wallman, J. (2001). Differences in time course and visual
requirements of ocular responses to lenses and diffusers. Investigative
Ophthalmology & Visual Science, 42, 575–583.
Lauber, J. K. (1991). Three avian eye enlargement protocols as myopia models:
Effects of pharmacological intervention. Journal of Ocular Pharmacology and
Therapeutics, 7, 65–75.
Livak, K. J., & Schmittgen, T. D. (2001). Analysis of relative gene expression data
using real-time quantitative PCR and the 2DDCt method.Methods, 25, 402–408.
McFadden, S. A., & Wildsoet, C. (2009). Mammalian eyes need an intact optic nerve
to detect the sign of defocus during emmetropisation. Investigative
Ophthalmology & Visual Science, 50. ARVO E-Abstract 1620.
McKanna, J. A., & Casagrande, V. A. (1981). Atropine affects lid-suture myopia
development. Documenta Ophthalmologica Proceedings Series, 28, 187–192.
Morgan, I. G., Ashby, R. S., & Nickla, D. L. (2013). Form deprivation and lens-induced
myopia: Are they different? Ophthalmic and Physiological Optics, 33, 355–361.
Mutti, D. O., Mitchell, G. L., Jones, L. A., Friedman, N. E., Frane, S. L., Lin, W. K., et al.
(2005). Axial growth and changes in lenticular and corneal power during
emmetropization in infants. Investigative Ophthalmology & Visual Science, 46,
3074–3080.
Nickla, D. L., & Wallman, J. (2010). The multifunctional choroid. Progress in Retinal
and Eye Research, 29, 144–168.
Nickla, D. L., Wildsoet, C., & Wallman, J. (1998). The circadian rhythm in intraocular
pressure and its relation to diurnal ocular growth changes in chicks.
Experimental Eye Research, 66, 183–193.
Norton, T. T. (1999). Animal models of myopia: Learning how vision controls the
size of the eye. ILAR Journal, 40, 59–77.
Norton, T. T., Amedo, A. O., & Siegwart, J. T. Jr., (2006). Darkness causes myopia in
visually experienced tree shrews. Investigative Ophthalmology & Visual Science,
47, 4700–4707.
Norton, T. T., Essinger, J. A., & McBrien, N. A. (1994). Lid-suture myopia in tree
shrews with retinal ganglion cell blockade. Visual Neuroscience, 11, 143–153.
Norton, T. T., Siegwart, J. T., Jr., & Amedo, A. O. (2006). Effectiveness of hyperopic
defocus, minimal defocus, or myopic defocus in competition with a
myopiagenic stimulus in tree shrew eyes. Investigative Ophthalmology & Visual
Science, 47, 4687–4699.
L. He et al. / Vision Research 102 (2014) 52–63 63Norton, T. T., Siegwart, J. T., German, A. J., Robertson, J., & Wu, W. W. (2000).
Comparison of cycloplegic streak retinoscopy with autorefractor measures in
tree shrew eyes with, and without, induced myopia. Investigative Ophthalmology
& Visual Science, 41. ARVO Abstract 563.
Norton, T. T., Wu, W. W., & Siegwart, J. T. Jr., (2003). Refractive state of tree shrew
eyes measured with cortical visual evoked potentials. Optometry and Vision
Science, 80, 623–631.
Raviola, E., & Wiesel, T. N. (1985). An animal model of myopia. New England Journal
of Medicine, 312, 1609–1615.
Rohrer, B., Negishi, K., Tao, J., & Stell, W. K. (1993). A role for basic ﬁbroblast growth
factor (bFGF) in the visually guided regulation of eye growth in the chick.
Investigative Ophthalmology & Visual Science, 34. ARVO Abstract 2489.
Schaeffel, F., Hagel, G., Bartmann, M., Kohler, K., & Zrenner, E. (1994). 6-Hydroxy
dopamine does not affect lens-induced refractive errors but suppresses
deprivation myopia. Vision Research, 34, 143–149.
Schaeffel, F., & Howland, H. C. (1988). Mathematical model of emmetropization in
the chicken. Journal of the Optical Society of America, 5, 2080–2086.
Schaeffel, F., Troilo, D., Wallman, J., & Howland, H. C. (1990). Developing eyes that
lack accommodation grow to compensate for imposed defocus. Visual
Neuroscience, 4, 177–183.
Schippert, R., Brand, C., Schaeffel, F., & Feldkaemper, M. P. (2006). Changes in scleral
MMP-2, TIMP-2 and TGFb-2 mRNA expression after imposed myopic and
hyperopic defocus in chickens. Experimental Eye Research, 82, 710–719.
Shelton, L., Troilo, D., Lerner, M. R., Gusev, Y., Brackett, D. J., & Rada, J. S. (2008).
Microarray analysis of choroid/RPE gene expression in marmoset eyes
undergoing changes in ocular growth and refraction. Molecular Vision, 14,
1465–1479.
Siegwart, J. T., Jr., & Norton, T. T. (1998). The susceptible period for deprivation-
induced myopia in tree shrew. Vision Research, 38, 3505–3515.Siegwart, J. T., Jr., & Norton, T. T. (2005). Selective regulation of MMP and TIMP
mRNA levels in tree shrew sclera during minus lens compensation and
recovery. Investigative Ophthalmology & Visual Science, 46, 3484–3492.
Smith, E. L., III, Hung, L. F., & Harwerth, R. S. (1999). Developmental visual system
anomalies and the limits of emmetropization. Ophthalmic and Physiological
Optics, 19, 90–102.
Stone, R. A., McGlinn, A. M., Baldwin, D. A., Tobias, J. W., Iuvone, P. M., & Khurana, T.
S. (2011). Image defocus and altered retinal gene expression in chick: Clues to
the pathogenesis of ametropia. Investigative Ophthalmology & Visual Science, 52,
5765–5777.
Summers, J. A. (2013). The choroid as a sclera growth regulator. Experimental Eye
Research, 114, 120–127.
Troilo, D., Gottlieb, M. D., & Wallman, J. (1987). Visual deprivation causes myopia in
chicks with optic nerve section. Current Eye Research, 6, 993–999.
Troilo, D., & Wallman, J. (1991). The regulation of eye growth and refractive state:
An experimental study of emmetropization. Vision Research, 31, 1237–1250.
Wallman, J., & Winawer, J. (2004). Homeostasis of eye growth and the question of
myopia. Neuron, 43, 447–468.
Wildsoet, C. (2003). Neural pathways subserving negative lens-induced
emmetropization in chicks – Insights from selective lesions of the optic nerve
and ciliary nerve. Current Eye Research, 27, 371–385.
Yew, K., & Wildsoet, C. F. (2003). The usual effects of high-power negative lens and
diffusers show differential susceptibility to disruption to the diurnal light cycle.
Investigative Ophthalmology & Visual Science, 44. ARVO E-Abstract 1979.
Zhang, Y., Liu, Y., & Wildsoet, C. F. (2012). Bidirectional, optical sign-dependent
regulation of BMP2 gene expression in chick retinal pigment epithelium.
Investigative Ophthalmology & Visual Science, 53, 6072–6080.
